Mesoblast (NASDAQ:MESO) Trading Up 9.3% – What’s Next?

Mesoblast Limited (NASDAQ:MESO) rose 9.3% during trading on Wednesday . The stock traded as high as $15.73 and last traded at $15.6560. Approximately 79,609 shares changed hands during trading, a decline of 69% from the average daily volume of 256,238 shares. The stock had previously closed at $14.32.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Mesoblast in a research note on Thursday, January 22nd. Two analysts have rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Mesoblast currently has an average rating of “Moderate Buy”.

Mesoblast Stock Performance

The firm has a market cap of $2.03 billion, a price-to-earnings ratio of -17.88 and a beta of 2.17. The company has a debt-to-equity ratio of 0.10, a current ratio of 1.58 and a quick ratio of 1.41. The firm has a fifty day simple moving average of $16.47 and a two-hundred day simple moving average of $16.90.

Mesoblast (NASDAQ:MESO) last posted its quarterly earnings data on Thursday, January 29th. The company reported ($0.16) earnings per share (EPS) for the quarter. The firm had revenue of $25.67 million for the quarter. On average, analysts expect that Mesoblast Limited will post -0.7 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of MESO. Mirae Asset Global Investments Co. Ltd. lifted its stake in Mesoblast by 30.6% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,383 shares of the company’s stock valued at $43,000 after acquiring an additional 558 shares during the period. Vanguard Personalized Indexing Management LLC grew its position in Mesoblast by 5.4% during the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 14,047 shares of the company’s stock worth $226,000 after purchasing an additional 716 shares during the period. JPMorgan Chase & Co. grew its position in Mesoblast by 55.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,831 shares of the company’s stock worth $46,000 after purchasing an additional 1,012 shares during the period. Choreo LLC lifted its holdings in shares of Mesoblast by 15.1% in the 4th quarter. Choreo LLC now owns 12,225 shares of the company’s stock valued at $227,000 after buying an additional 1,600 shares during the period. Finally, Caitong International Asset Management Co. Ltd acquired a new position in shares of Mesoblast in the 4th quarter valued at about $32,000. 1.43% of the stock is owned by institutional investors and hedge funds.

Mesoblast Company Profile

Mesoblast Limited is a global leader in allogeneic cellular medicines, focused on developing treatments for inflammatory and immunologic diseases. Founded in 2004 by Dr. Silviu Itescu, the company builds on proprietary mesenchymal lineage cell technology to create off-the-shelf, donor-derived therapies. These therapies are designed to modulate immune responses and promote tissue repair in conditions where existing medical options are limited or ineffective.

The company’s most advanced product, Alofisel® (darvadstrocel), has been approved in Europe for the treatment of complex perianal fistulas in adults with Crohn’s disease.